Skip to main content
Tom van Meerten

I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study
Published in: American Journal of Hematology
For elderly frail patients with diffuse large B-cell lymphoma (DLBCL), an attenuated chemo-immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-miniCHOP) was introduced as a treatment option as from 2014 onward in the Netherlands. Although R-miniCHOP is more tolerable, reduction of chemotherapy could negatively affect survival compared to R-CHOP. The aim of this analysis was to assess survival of patients treated with R-miniCHOP compared to R-CHOP. DLBCL patients ≥65 years, newly diagnosed in 2014-2020, who received ≥1 cycle of R-miniCHOP or R-CHOP were identified in the Netherlands Cancer Registry,...
D Al-Sarayfi, M Brink, M E D Chamuleau, R Brouwer, R S van Rijn, D Issa, W Deenik, G Huls, R Mous, J S P Vermaat, A Diepstra, J M Zijlstra, T van Meerten, M Nijland
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
Published in: Cancers
Janneke W. de Boer, Kylie Keijzer, Elise R. A. Pennings, Jaap A. van Doesum, Anne M. Spanjaart, Margot Jak, Pim G. N. J. Mutsaers, Suzanne van Dorp, Joost S. P. Vermaat, Marjolein W. M. van der Poel, Lisanne V. van Dijk, Marie Jose Kersten, Anne G. H. Niezink, Tom van Meerten
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
Published in: Cancers
The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after ≥2 lines of systemic therapy referred for axi-cel treatment between May 2020–May...
on behalf of the Dutch CAR-T Tumorboard Consortium, Anne M. Spanjaart, Elise R.A. Pennings, Pim G.N.J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, Janneke W. de Boer, Anne G.H. Niezink, Milan Kos, Joost S.P. Vermaat, Aniko Sijs-Szabo, Marjolein W.M. van der Poel, Inger S. Nijhof, Maria T. Kuipers, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Jeanette K. Doorduijn, Yasmina I.M. Serroukh, Monique C. MinnemaTom van Meerten, Marie José Kersten
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
Published in: Blood Advances
Janneke W de Boer, Elise R A Pennings, Ankie Kleinjan, Jaap A van Doesum, Anne M Spanjaart, Pim G N J Mutsaers, Margot Jak, Marjolein W M van der Poel, Maria T Kuipers, Judit A Adam, Arjan Diepstra, Lianne Koens, Suzanne van Dorp, Joost S P Vermaat, Anne G H Niezink, Marie José Kersten, Tom van Meerten
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
Published in: EClinicalMedicine
Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality.  Methods: In this cohort study, conducted at 5 sites in the Netherlands, we compared antibody concentrations 28 days after 4 mRNA vaccinations (3-dose primary series plus 1 booster vaccination) in SARS-CoV-2 naive, immunocompromised patients with haematological malignancies to those obtained by age-matched, healthy individuals who had received the standard primary 2-dose mRNA vaccination schedule followed by a first booster mRNA vaccination....
COBRA KAI study team, Quincy Hofsink, Sabine Haggenburg, Birgit I. Lissenberg-Witte, Annoek E.C. Broers, Jaap A. van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan van Meerloo, Judith A. Burger, Joey H. Bouhuijs, Gaby P. Smits, Dorine Wouters, Ester M.M. van Leeuwen, Hetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Nynke Y. RotsJosine van Beek, Mirjam H.M. Heemskerk, Kazimierz Groen, Tom van Meerten, Pim G.N.J. Mutsaers, Marit J. van Gils, Abraham Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof, Margriet J. Dijkstra